Release Date: August 31, 2021
Expiration Date:
August 31, 2022
The Medical Crossfire®, one of PER's® signature educational formats, is a video based program in which a panel of distinguished experts engage in spirted discussions about a clinical topic. In this activity, 4 thought leaders explore the emerging data surrounding sustained delivery Anti-Vascular Endothelial Growth Factor (Anti-VEGF) therapies for the management of neovascular retinal diseases like neovascular Age-Related Macular Degeneration (nAMD). This lively debate will place new developments into clinical context to help you optimize care for patients with neovascular retinal diseases.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
This online educational activity is directed toward ophthalmologists and retinal specialists. Other health care professionals involved in the treatment of patients with nAMD are also invited to participate.
Upon successful completion of this activity you should be better prepared to:
The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
Chair
Arshad M. Khanani, MD, MA
Clinical Associate Professor
University of
Nevada
Reno School of Medicine Managing Partner
Director of Clinical
Research
Director of Fellowship
Sierra Eye Associates
Reno,
NV
Disclosures: Grant Research Support: Genentech,
Inc., Adverum Biotechnologies, Regenxbio, Inc.;Consultant: Genentech,
Adverum Biotechnologies, Regenxbio, Inc.;Speakers Bureau: Genentech,
Inc.
Faculty
Sophie J. Bakri, MD
Chair, Department of
Ophthalmology
Mayo Clinic
Rochester, MN
Disclosures: Consultant: Adverum Biotechnologies,
Allergan plc, Alimera Sciences, Inc., Apellis Pharmaceuticals, Kala
Pharmaceuticals, Inc., Novartis, Outlook Therapeutics, Inc., F. Hoffmann-La
Roche AG, Regenexbio, Inc., Re-Vana Therapeutics, Ltd., Zeiss Pharma, Ltd.
Peter K. Kaiser, MD
Professor of Ophthalmology
Chaney
Family Endowed Chair in Ophthalmology Research
Cleveland Clinic
Lerner
College of Medicine
Cole Eye Institute
Cleveland, OH
Disclosures: Consultant: Allergan plc, Kanghong
Pharmaceutical, Regeneron Pharmaceuticals, Bayer Corporation, Novartis
Pharmaceuticals, Kodiak Sciences
Carl D. Regillo, MD
Professor of Ophthalmology
Thomas
Jefferson University
Chief Retina Service
Wills Eye Hospital
Philadelphia,
PA
Disclosures: Grant Research Support: Adverum
Biotechnologies, Allergan plc, Annexon Biosciences, Astellas Pharma, Inc.,
Chengdu Kanghong Pharma, EyePoint Pharmaceuticals, Inc., Graybug Vision,
Iveric Bio, Kodiak Sciences, Inc., Lineage Cell Therapeutics, NGM
Biopharmaceuticals, Inc., Notal Vision, Novartis Pharmaceuticals, Opthea,
Ltd., Regeneron Pharmaceuticals, RegenX, Bio, Inc.;
Consultant: Adverum Biotechnologies, Alderya Therapeutics, Allergan
plc, Annexon Biosciences, Aviceda Therapeutics, Chengdu Kanghong Pharma,
Eyepoint Pharmaceuticals, Inc., Genentech, Inc., Graybug Vision, Iveric Bio,
Kodiak Sciences, Inc., Lineage Cell Therapeutics, Merck, Co., NGM
Biopharmaceuticals, Inc., Notal Vision, Novartis Pharmaceuticals, Ocugen,
Inc., Opthea, Ltd., Stealth BioTherapeutics, Takeda Pharmaceutical Company
Limited, Tha Pharmaceuticals Limited, Zeiss Pharma Ltd.;
Stock Shareholder: Iveric Bio.
PER® mitigated all COI for faculty staff and planners prior to the start of this activity by using a multistep process.
This activity may or may not discuss investigational unapproved or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
ENROLL TODAY
Register now to gain access to this course.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
